IL-2 Plasmid Electroporation: From Preclinical Studies to Phase I Clinical Trial
Electroporation (EP)-assisted intralesional delivery of Interleukin-2 (IL-2) plasmid (pDNA) has the potential to increase the local concentration of the expressed cytokine for an extended time in the injected tumors while minimizing its systemic concentration, in comparison with systemic delivery of the recombinant cytokine. Nonclinical Investigational New Drug application-enabling studies were performed in mice to evaluate the effect of intratumoral administration of murine IL-2 pDNA on local expression and systemic distribution of IL-2 transgene as well as the inhibition of established tumor growth. The safety of repeated administrations of a human IL-2 pDNA product candidate with EP was evaluated in rats. Following the nonclinical safety and efficacy studies, a human IL-2 pDNA product candidate intralesionally administered with EP to metastatic melanoma patients is currently being investigated in a phase I clinical trial.
- 何杰金氏病 Hodgkin′s disease
- 面部疤痕、缺損與畸形
- 舒爾策氏雙胎形成 Schultze′s double formation
- Optimization of the Molecular Dynamics Method for Simulations of DNA and Ion Transport Through Biological Nanopores
- 神經(jīng)節(jié) nerve ganglion
- 向電性 electrotropism,galvanotropism
- 陸源沉積物 terrigenous sediment
- Nat Methods:2014年值得關(guān)注的技術(shù)
- 噬神經(jīng)元的腺病毒載體的構(gòu)建
- 銀染核仁形成區(qū)的光鏡和電鏡標(biāo)本制備及觀察